In contrast to current treatments that contain insecticides such as lindane, malathion, permethrin and pyrethrins that are neurotoxic to insects, Piedmont’s patented treatment utilizes an insecticide-free, non-neurotoxic formulation.
Using ingredients commonly found in cosmetics and medications, the novel patented product works by quickly dissolving the wax that covers the outer shell of all insects, resulting in the dehydration and death of the parasites. The treatment is colorless, odorless, and does not require use of a special lice comb.
Piedmont is optimistic that successful completion of phase III trials and approval for marketing would place its treatment as the first and only one with this mode of action to go through FDA’s approval process. Furthermore, due to its unique mode of action, it is unlikely that lice will develop resistance to it.
Head lice are human parasites that live on the scalp and feed on blood, causing irritation, itching and sores. According to the US Centers for Disease Control and Prevention (CDC), infestation is common around the world, and is found primarily among young schoolchildren. The parasites affect all socioeconomic groups, and there are an estimated six to 12 million cases of lice each year in the US alone.